anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a measurement method of paeoniflorin content in ginseng and astragalus stomach strengthening granules. The method comprises the preparation of reference solution, the special preparation of sample solution and the final Phase chromatography by N-dimethyl aniline. The concrete steps are: using the octadecyl silane bonded silica as loading agent, using methanol - water - phosphoric acid solution with volume concentration 25 to 75 to 0.1 as mobile phase, adjusting the testing wavelength to 230 nanometres and the paeoniflorin peak value calculated according to theoretical plate number is not supposed to be less than 2000. At the measurement, 20 ml solution is taken respectively from reference solution and sample solution by precise drawing and is poured into the liquid chromatograph device for the measurement to get the content of paeoniflorin. By adopting the HPLC method (high performance liquid chromatography), the invention succeeds in measuring the content of paeoniflorin, one of the active constituents of the main ingredient white peony root in the ginseng and astragalus stomach strengthening granules. The method can greatly enhance the precision of the content measurement of paeoniflorin and thus enabling a better control of the product quality.
Long-term facilitation (LTF) of respiration has been mainly initiated by intermittent hypoxia and resultant chemoreceptor stimulation in humans. Comparable levels of chemoreceptor stimulation can occur in combined exercise and carbon dioxide (CO2) inhalation and lead to LTF. This possibility was supported by data collected during combined interval exercise and 3% inhaled CO2 in seven normal subjects. These data were further analyzed based on the dynamics involved using mathematical models in this study. Previously estimated peripheral chemoreceptor sensitivity during light exercise (40 W) with air or 3% inhaled CO2 approximately doubled resting sensitivity. Ventilation after a delay increased by 17.0 ± 2.48 L/min (p < 0.001) during recovery following 45% maximal oxygen uptake ([Formula: see text] ) exercise consistent with LTF which exceeded what can be achieved with intermittent hypoxia. Model fitting of the dynamic responses was used to separate neural from chemoreceptor-mediated CO2 responses. Exercise of 45% [Formula: see text] was followed by ventilation augmentation following initial recovery. Augmentation of LTF developed slowly according to second-order dynamics in accordance with plasticity involving a balance between self-excitatory and self-inhibitory neuronal pools.
The participant will perform sham control exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength. The speech language pathologist will call or conduct videoconference visits with participants 1, 3, 5, 7 and 9 weeks after the baseline assessment to provide re-training (if needed) and to troubleshoot technical issues related to the use of the app.
Provided are a light source unit for an endoscope and an endoscopy system, which clarify the color difference between a first dye and a second dye in an observation image. The light source unit has a white LED light source and a band limiting section. The white LED light source has an excitation light source that emits blue excitation light and a phosphor layer that emits yellow fluorescence upon receipt of the excitation light. As a mixture of the fluorescence and part of the excitation light, the white LED light source outputs light having an intensity spectrum continuous across blue, green and red regions. The band limiting section reduces part of the output light in a wavelength band of not lower than a threshold. The threshold is not less than 650 nm. At the threshold, the first dye (pyoktanin) has an optical reflectance of not less than a constant value, whereas the second dye (indigocarmine) has an optical reflectance of substantially zero.
To test the effectiveness of the Tip Stim device, each patient received (alternating) both the experimental and control treatments in a specific sequence to assess the coordination of human hand movement and the grip strength. The first therapy with the use of Tip Stim parameters (Ratio current time to pause time: 2 sec :5 sec; Ramp (rise time impulse): 0,3 sec; Frequency: 20 Hz; Pulse width: 300 µs). Another session (putting on the glove without setting any parameters) took place after a week (time to mute the effects of the intervention). The duration of each therapy session is 60 minutes. After the first therapeutic session and after a week, the parameters of movement coordination and hand grip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) (fig. 1) and lying (with stabilization) (fig. 2), and with a different position of the examined upper limb. During the first examination, the subject sat on a treatment table, feet resting on the floor. Upper limb examined in adduction, with bent elbow joint in the intermediate position between pronation and supination of the forearm. In the supine examination, the upper limb was stabilized against the subject's body (adduction in the shoulder joint, flexion in the elbow joint in an intermediate position). In each of the starting positions, first after putting on the glove, the range of passive motion in the radial-wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Eventually, they were asked to make movements as quickly and as fully as possible. Measurement of the grip force with a dynamometer was performed in both analyzed starting positions after testing the ranges of motion and speed/frequency.

The Hand Tutor device and the EH 101 electronic hand dynamometer measuring the strength of the handgrip (measurement error 0.5 kg / 1 lb) were used to test the parameters of motor coordination and grip strength. The Hand Tutor is a device with a rehabilitation program and the ability to measure the range of passive and active movement, deficits of movement (error of measurement, 5 - 10 mm) as well as the speed/frequency of movement (error of measurement, 0,5 cycle/sec.).
Nitrofurantoin Oral Suspension, USP contains nitrofurantoin, a synthetic nitrofuran antibacterial agent specific for urinary tract infections. The chemical name is 1-[[(5-nitro-2-furanyl)methylene]amino]-2,4­imidazolidinedione monohydrate. The molecular formula is C8H6N4O5·H2O and the molecular weight is 256.17. The structural formula is:

Nitrofurantoin is a stable, yellow, crystalline compound.

  


Nitrofurantoin Oral Suspension, USP is available as a lemon-yellow liquid with cherry flavor, free from extraneous particles for oral administration containing 25 mg/5 mL of nitrofurantoin. Nitrofurantoin Oral Suspension, USP also contains the following inactive ingredients: citric acid, artificial cherry flavor, glycerin, methylparaben, propylparaben, purified water, sodium citrate, sucralose, simethicone emulsion, and xanthan gum.
The present invention discloses a composition with a laxative function and a preparation method, a formulation and an application thereof. The composition comprises the following ingredients in parts by weight: phytophagy food extract 1-10 parts, polyfructosan 60-80 parts and honey 10-39 parts. The preparation method includes the following steps: crushing raw material phytophagy food, extracting the phytophagy food, filtrating the extract, combining filtrate, and concentrating the filtrate; and adding the polyfructosan and propolis into the phytophagy food extract obtained from the above step, mixing the mixture evenly, drying the mixture to obtain the composition, and putting the composition into storage after the composition is sterilized, packaged and tested. The formulation is powder, tablet, capsule and oral liquid preparations prepared by adding food acceptable adjuvant materials into the composition. The application is to apply the above-mentioned composition to preparation of food having a laxative function. The composition can give full play to specialties of any single species, and achieve better results in terms of having the laxative function. Meanwhile, the natural extract may increase aroma, color and flavor, and a better color and luster and a better taste can be realized. The composition is conducive to long-term use by patients.
The invention discloses recombinant human epidermal growth factor powder which is prepared from the following components in percentage by mass: 0.01-0.05% of recombinant human epidermal growth factor, 1.2-3.5% of mannitol, 2-8% of glycine, 0.01-0.08% of human serum albumin and the balance of first purified water. The invention also provides a preparation method of the recombinant human epidermal growth factor powder. The invention also provides a skin repairing agent. The invention also provides a preparation method of the skin repairing agent. The invention also provides a use method of the skin repairing agent. The recombinant human epidermal growth factor in the powder can promote the proliferation of epidermal cells and the metabolism of normal epidermal cells, ensure the activity of the recombinant human epidermal growth factor and improve the action efficiency of the recombinant human epidermal growth factor.
Patients included in this group underwent full-mouth scaling followed by root planning in the necessary areas. At the 3-week follow-up session, periodontal surgery was not planned. Periodontal records were maintained, and surveys were administered at follow-up visits.
The present invention provides a Chinese medical preparation for treating breast impediment, which belongs to the technical field of a Chinese medicine. The present invention is mainly characterized in that the Chinese medical preparation is prepared by using Chinese thorowax root, magnolia officinalis, etc. which have the functions of coursing the liver, rectifying the spleen and descending turbidity as principal medicines, using platycodon root, white mustard seed, tuckahoe, etc. which has the functions of disinhibit the lung, resolving phlegm and promoting the circulation of qi to induce diuresis as minister medicines, using ginseng, hemlock parsley, astragalus root, etc. which has the functions of strengthening body resistance, benefiting vital energy, promoting blood flow, resolving phlegm, increasing yang and raising the fall as assistant medicines and using walnut kernel, radix glycyrrhiza, etc. which has the functions of benefiting qi, nourishing the blood, supplementing the kidney to promote qi absorption, loosening the bowel to relieve constipation, relieving mental stress, relieving asthma and inducing resuscitation as envoy medicines. The present invention achieves the effects of dispersing phlegm, removing stasis, activating qi, calming the mind and eliminating thoracic obstruction by the compatibility of the medicines and has the obvious advantages and therapeutic effects of no toxic or side effect, no adverse reaction, rapid therapeutic effect, low medicine expense, short treatment period, high cure rate, no recrudescence, etc.
The present invention discloses a Chinese medicine for preventing and treating depression and hypothermia, which comprises polygala root, curcuma root, rhizoma cyperi and glycyrrhiza. The Chinese medicine of the present invention overcomes the toxicity of chemical antidepressants, and the disadvantage that the effect of domestic and foreign antidepressant plant medicines on the organism objective physiological index is not obvious is overcome. The body temperature of the mouse reserpine depression model is obviously raised, and low, middle and high doses are capable of raising the temperature by 1.69 DEG C, 2.22 DEG C and 2.63 DEG C. The content of norepinephrine (NE), dopamine (DA) and 5-hydroxytryptamine (5-HT) in brain tissues is obviously higher than that of a reserpine depression model set. The mouse depressive symptom is also obviously reduced as compared with a comparison set, and the phenomenon that upper eyelids drop can be improved. The time taken by the mouse to suspend the tail and do not move is shortened, and the autonomous mobility is enhanced. The preparation of the Chinese medicine has obvious therapeutical effect on the depression and is safe and ideal antidepressant with specific curative effect and excellent development prospects.
E learning provides education at a generally lower cost and engages learners at a time and location that is most appropriate for them. Recent calls for reform in medical education and training have emphasized the use of information technology-empowered learning. This was enhanced more in the COVID-19 era . Some international organizations, such as the World Health Organization (WHO), have acknowledged e-learning as a helpful tool for healthcare education, particularly in developing countries. Nevertheless, the use of e-learning by the faculty members and students stayed minimum for uploading lecture notes, course books, feedbacks, and providing marks until the COVID-19 pandemic raised that need. This study aimed to evaluate faculty and students' knowledge and attitudes toward e-learning at the emergence of COVID-19 and identify the potential requirements for implementing e-learning.

An online survey was distributed to a sample of 190 faculty and 1706 students of a medical university in Iraq. Knowledge and attitudes towards e-learning were studied
The intervention will consist of identification of 3-5 therapy goals using GAS (Turner-Stoke, 2009), joint planning with a therapist to achieve these goals during the program, and a robotic therapy plan. The robotic therapy plan will be negotiated with participants and consist of 3 sessions (about 1 h) per week for 8 weeks. The plan will detail the types of robotic activities (e.g. selection of interactive activities and games) to be completed by the participant. Homework relevant to participants' therapy goals will also be developed after each session. The intervention for each participant will be 24 robotic therapy sessions and 10 progress review sessions. The robotic system includes a tabletop 2-degree of freedom haptic robot that provides assisted and resisted shoulder and elbow movement therapy (Lu et. al, 2012). Interactive games are used with the system to engage and motivate participants to continue therapy.
The volume of distribution of tramadol was 2.6 and 2.9 L/kg in male and female subjects, respectively, following a 100 mg intravenous dose. The binding of tramadol to human plasma proteins is approximately 20% and binding also appears to be independent of concentration up to 10 mcg/mL. Saturation of plasma protein binding occurs only at concentrations outside the clinically relevant range.

Acetaminophen appears to be widely distributed throughout most body tissues except fat. Its apparent volume of distribution is about 0.9 L/kg. A relative small portion (~20%) of acetaminophen is bound to plasma protein.
SSA contracted with Mathematica to conduct an independent evaluation of RETAIN Kentucky. Under the RETAIN model medical providers receive training and incentives to use occupational health best practices. The state agency also coordinates SAW/RTW services for the enrollee, fosters communication among RETAIN stakeholders about the treatment enrollee returning to work, and monitors the enrollee's medical and employment progress. RETAIN Kentucky also provides individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support.

Kentucky uses a multi-method approach toward recruitment that includes referrals from medical providers, employers, Office of Vocational Rehabilitation, workforce and disability management organizations, community partners, and word of mouth. A return-to-work (RTW) coordinator conducts intake, determines enrollees' eligibility, and randomly assigns each enrollee to either a treatment group that is eligible to receive the full set of RETAIN intervention activities or a control group that is not. The evaluation team then compares the outcomes of the two groups and gathers evidence on how each RETAIN project shaped the outcomes of enrollees who were eligible for its services, regardless of whether they participated in those services. Data sources include enrollment data, surveys, administrative records, program data, and qualitative data.
Gastroesophageal reflux disease (GERD) is the sole cause of chronic cough in up to 20-40% of all cases, and majority of these patients with GERD-induced cough have no classic "heartburn" symptoms. This important cause of cough can thus be difficult to detect. Non-invasive radiologic tests for GERD such as barium swallow is imperfectly sensitive in subjects with GERD-induced cough. The 24 hour pH probe, which continuously monitors esophageal pH and can correlate cough events with reflux events, is considered to be the gold standard test. However, this test is expensive, invasive, and not universally available.

The goal of the current study is to compare simultaneous measurements of esophageal pH with exhaled breath condensate pH after cough episodes, in patients with symptomatic cough. The cause of cough will be determined by a standard protocol, which includes 24 hour pH probe studies, and assessment for asthma, upper airway causes and sinus disease, and medication effects. All subjects will undergo 24 hour pH monitoring. During this monitoring period, they press an event button on the pH recording device to indicate a cough episode. After six such events, they will immediately perform an EBC collection, and EBC pH will subsequently be analyzed. Differences between pH changes in the group with cough cause by GERD will be compared to pH measurements in the group with cough but no GERD, to determine the sensitivity and specificity of pH changes for discriminating between the two groups, and optimal threshold values for pH changes in EBC.
INTRODUCTION: Among youth with type 1 diabetes (T1D), longitudinal poor glycemic control is associated with adverse socioeconomic conditions at the neighborhood level. Child Opportunity Index (COI), which encompasses measures of education, health, environment, social, and economic factors, is associated with obesity in youth but has not been evaluated in youth with new-onset T1D or type 2 diabetes (T2D). We hypothesized that lower COI would be associated with adverse clinical outcomes at diabetes diagnosis, and due to differing risk factors and pathophysiology, that youth with new-onset T2D would have lower COI than youth with T1D.
RESEARCH DESIGN AND METHODS: Retrospective cohort of youth with new-onset diabetes admitted to a large academic pediatric hospital. COI was compared by diabetes type using t-tests and Χ2 tests. Multivariable linear and logistic regression analyses were used to evaluate associations between COI and clinical characteristics, stratified by diabetes type and adjusted for age and sex.
RESULTS: The cohort (n=484) differed in race and age by diabetes type (T1D: n=389; 10.0% black, 81.2% white; age 9.6±0.2 years; T2D: n=95; 44.2% black, 48.4% white; age 14.8±0.3 years). Youth with T2D had lower COI (p<0.001). Low COI was associated with diabetic ketoacidosis in T1D and T2D. Black youth with low COI had the highest hemoglobin A1c among youth with T2D and the highest obesity prevalence among youth with T1D.
CONCLUSIONS: COI is associated with differing characteristics at diagnosis in youth-onset T1D and T2D but is worse among youth with T2D overall. These findings underscore the need to address socioeconomic adversity when designing interventions to reduce T2D risk and to improve outcomes at diabetes diagnosis in youth.
Hydromorphone hydrochloride suppositories contain hydromorphone, a Schedule II controlled substance. As an opioid, hydromorphone hydrochloride exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed hydromorphone hydrochloride suppositories. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing hydromorphone hydrochloride suppositories, and monitor all patients receiving hydromorphone hydrochloride suppositories for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as hydromorphone hydrochloride suppositories, but use in such patients necessitates intensive counseling about the risks and proper use of hydromorphone hydrochloride suppositories along with intensive monitoring for signs of addiction, abuse, and misuse.

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing hydromorphone hydrochloride suppositories. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see Patient Counseling Information (17)]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
<P>PROBLEM TO BE SOLVED: To provide a new polypeptide, etc., useful e.g. for the development of an agent for the prevention and treatment of the infectious diseases with Staphylococcus aureus.  <P>SOLUTION: The invention provides a polypeptide containing a specific amino acid sequence, etc., derived from Staphylococcus aureus having T-cell proliferation activity, a polynucleotide encoding the polypeptide, a polypeptide crystal, etc. An agent for the prevention and treatment of infectious diseases with Staphylococcus aureus having a new mechanism can be developed by the use of the polypeptide, etc. Especially the in-silico development of an agent for the prevention and treatment of infectious diseases with Staphylococcus aureus can be performed by using a structure coordinate obtained by the X-ray structure analysis of the crystal of the present invention.  <P>COPYRIGHT: (C)2007,JPO&INPIT